ArriVent BioPharma (AVBP) EBIT (2023 - 2026)
ArriVent BioPharma (AVBP) posted EBIT of -$46.1 million for Q1 2026, down 18.77% sequentially from -$38.8 million in Q4 2025, and up 30.94% YoY from -$35.2 million in Q1 2025.
ArriVent BioPharma (AVBP) EBIT (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported EBIT for 4 years, with the latest figure at -$46.1 million in Q1 2026.
- Quarterly EBIT rose 30.94% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$156.9 million (down 11.73% YoY) and the FY2025 annual result came in at -$177.5 million, down 88.25% from the prior year.
- EBIT declined to -$46.1 million in Q1 2026 per AVBP's latest filing, from -$38.8 million in the prior quarter.
- Over five years, EBIT peaked at -$12.2 million in Q1 2023 and troughed at -$66.8 million in Q1 2025.
- A 4-year average of -$30.2 million and a median of -$24.2 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2025 and 2026: EBIT sank 222.98% in 2025, then soared 30.94% in 2026.
- Over 4 years, EBIT stood at -$23.1 million in 2023, then declined by 2.54% to -$23.7 million in 2024, then slumped by 63.78% to -$38.8 million in 2025, then declined by 18.77% to -$46.1 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$46.1 million, -$38.8 million, and -$38.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -52.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.69 Mn |
| Mar 31, 2026 | -46.11 Mn |
| Dec 31, 2025 | -38.82 Mn |
| Sep 30, 2025 | -38.32 Mn |
| Jun 30, 2025 | -33.62 Mn |
| Mar 31, 2025 | -66.77 Mn |
| Dec 31, 2024 | -23.71 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | -25.70 Mn |
| Mar 31, 2024 | -20.67 Mn |
| Dec 31, 2023 | -23.12 Mn |
| Sep 30, 2023 | -16.72 Mn |
| Jun 30, 2023 | -22.58 Mn |
| Mar 31, 2023 | -12.17 Mn |